IDEXX Historical Balance Sheet
IDXX Stock | USD 516.10 1.84 0.36% |
Trend analysis of IDEXX Laboratories balance sheet accounts such as Total Current Liabilities of 999.1 M or Total Stockholder Equity of 1.6 B provides information on IDEXX Laboratories' total assets, liabilities, and equity, which is the actual value of IDEXX Laboratories to its prevalent stockholders. By breaking down trends over time using IDEXX Laboratories balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining IDEXX Laboratories latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether IDEXX Laboratories is a good buy for the upcoming year.
IDEXX Laboratories Inventory |
|
IDEXX |
About IDEXX Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of IDEXX Laboratories at a specified time, usually calculated after every quarter, six months, or one year. IDEXX Laboratories Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of IDEXX Laboratories and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which IDEXX currently owns. An asset can also be divided into two categories, current and non-current.
IDEXX Laboratories Balance Sheet Chart
IDEXX Laboratories Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how IDEXX Laboratories uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, IDEXX Laboratories' Cash And Short Term Investments are fairly stable compared to the past year. Net Receivables is likely to rise to about 480.3 M in 2024, whereas Net Debt is likely to drop slightly above 255.9 M in 2024. Add Fundamental
Total Assets
Total assets refers to the total amount of IDEXX Laboratories assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in IDEXX Laboratories books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on IDEXX Laboratories balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of IDEXX Laboratories are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Property Plant And Equipment Net
The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.Most accounts from IDEXX Laboratories' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into IDEXX Laboratories current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.At this time, IDEXX Laboratories' Cash And Short Term Investments are fairly stable compared to the past year. Net Receivables is likely to rise to about 480.3 M in 2024, whereas Net Debt is likely to drop slightly above 255.9 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 458.9M | 433.7M | 478.7M | 502.6M | Total Assets | 2.4B | 2.7B | 3.3B | 3.4B |
IDEXX Laboratories balance sheet Correlations
Click cells to compare fundamentals
IDEXX Laboratories Account Relationship Matchups
High Positive Relationship
High Negative Relationship
IDEXX Laboratories balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.8B | 2.3B | 2.4B | 2.7B | 3.3B | 3.4B | |
Other Current Liab | 322.9M | 415.6M | 458.9M | 433.7M | 478.7M | 502.6M | |
Total Current Liabilities | 725.3M | 582.8M | 763.6M | 1.2B | 951.5M | 999.1M | |
Total Stockholder Equity | 177.5M | 632.1M | 690.0M | 608.7M | 1.5B | 1.6B | |
Property Plant And Equipment Net | 533.8M | 555.2M | 587.7M | 649.5M | 702.2M | 737.3M | |
Net Debt | 897.3M | 524.6M | 779.2M | 1.2B | 493.9M | 255.9M | |
Retained Earnings | 1.6B | 2.2B | 2.9B | 3.6B | 4.4B | 4.7B | |
Accounts Payable | 72.2M | 74.6M | 116.1M | 110.2M | 110.6M | 116.2M | |
Cash | 90.3M | 383.9M | 144.5M | 112.5M | 453.9M | 476.6M | |
Non Current Assets Total | 1.2B | 1.2B | 1.5B | 1.6B | 1.8B | 1.9B | |
Non Currrent Assets Other | 299.0M | 337.2M | 397.4M | 425.6M | 448.5M | 470.9M | |
Cash And Short Term Investments | 90.3M | 383.9M | 144.5M | 112.5M | 453.9M | 476.6M | |
Net Receivables | 269.3M | 331.4M | 368.3M | 400.6M | 457.4M | 480.3M | |
Common Stock Shares Outstanding | 87.5M | 86.7M | 86.6M | 84.6M | 84.0M | 94.9M | |
Liabilities And Stockholders Equity | 1.8B | 2.3B | 2.4B | 2.7B | 3.3B | 3.4B | |
Inventory | 195.0M | 209.9M | 269.0M | 367.8M | 380.3M | 399.3M | |
Other Current Assets | 125.0M | 137.5M | 173.8M | 220.5M | 203.6M | 213.8M | |
Other Stockholder Equity | (1.4B) | (1.5B) | (2.2B) | (2.9B) | (2.9B) | (2.8B) | |
Total Liab | 1.7B | 1.7B | 1.7B | 2.1B | 1.8B | 1.9B | |
Total Current Assets | 679.6M | 1.1B | 955.7M | 1.1B | 1.5B | 1.6B | |
Non Current Liabilities Total | 929.3M | 1.1B | 983.6M | 902.2M | 823.8M | 865.0M | |
Intangible Assets | 58.5M | 52.5M | 99.0M | 97.7M | 84.5M | 74.5M | |
Short Long Term Debt Total | 987.7M | 908.5M | 923.7M | 1.3B | 947.9M | 995.3M | |
Short Term Debt | 288.8M | 50.0M | 148.5M | 654.0M | 325.0M | 208.6M | |
Property Plant And Equipment Gross | 614.5M | 646.3M | 1.3B | 649.5M | 1.6B | 1.7B | |
Accumulated Other Comprehensive Income | (46.2M) | (53.6M) | (53.5M) | (77.8M) | (71.2M) | (67.6M) | |
Common Stock Total Equity | 10.6M | 10.6M | 10.7M | 10.7M | 12.3M | 9.0M | |
Common Stock | 10.6M | 10.6M | 10.7M | 10.7M | 10.8M | 9.2M | |
Other Assets | 240.2M | 676.7M | 893.9M | 387.5M | 445.6M | 467.9M | |
Treasury Stock | (2.3B) | (2.6B) | (2.8B) | (3.6B) | (3.2B) | (3.1B) | |
Property Plant Equipment | 533.8M | 555.2M | 587.7M | 649.5M | 746.9M | 784.2M | |
Current Deferred Revenue | 41.5M | 42.6M | 40.0M | 37.9M | 37.2M | 25.0M | |
Good Will | 239.7M | 243.3M | 359.3M | 361.8M | 366.0M | 206.0M | |
Other Liab | 162.8M | 220.5M | 208.4M | 106.6M | 122.6M | 83.3M | |
Long Term Debt | 698.9M | 858.5M | 775.2M | 694.4M | 622.9M | 380.8M | |
Net Tangible Assets | (120.7M) | 336.2M | 690.0M | 149.3M | 134.3M | 141.1M | |
Noncontrolling Interest In Consolidated Entity | 264K | 280K | 352K | 707K | 813.1K | 853.7K | |
Retained Earnings Total Equity | 1.6B | 2.2B | 2.9B | 3.6B | 4.1B | 4.3B | |
Long Term Debt Total | 698.9M | 858.5M | 775.2M | 694.4M | 798.5M | 502.0M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.MSFT | Microsoft | |
GM | General Motors | |
CRM | Salesforce |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for IDEXX Stock analysis
When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Equity Valuation Check real value of public entities based on technical and fundamental data |
Is IDEXX Laboratories' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of IDEXX Laboratories. If investors know IDEXX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about IDEXX Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.102 | Earnings Share 10.31 | Revenue Per Share 44.828 | Quarterly Revenue Growth 0.071 | Return On Assets 0.2263 |
The market value of IDEXX Laboratories is measured differently than its book value, which is the value of IDEXX that is recorded on the company's balance sheet. Investors also form their own opinion of IDEXX Laboratories' value that differs from its market value or its book value, called intrinsic value, which is IDEXX Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IDEXX Laboratories' market value can be influenced by many factors that don't directly affect IDEXX Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IDEXX Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if IDEXX Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IDEXX Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.